Cargando…

Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC - PACS 01 randomized trial

INTRODUCTION: The PACS01 trial has demonstrated that a docetaxel addition to adjuvant anthracycline-based chemotherapy improves disease-free survival (DFS) and overall survival of node-positive early breast cancer (EBC). We searched for prognostic and predictive markers for docetaxel's benefit....

Descripción completa

Detalles Bibliográficos
Autores principales:	Jacquemier, Jocelyne, Boher, Jean-Marie, Roche, Henri, Esterni, Benjamin, Serin, Daniel, Kerbrat, Pierre, Andre, Fabrice, Finetti, Pascal, Charafe-Jauffret, Emmanuelle, Martin, Anne-Laure, Campone, Mario, Viens, Patrice, Birnbaum, Daniel, Penault-Llorca, Frédérique, Bertucci, François
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3326551/ https://www.ncbi.nlm.nih.gov/pubmed/22044691 http://dx.doi.org/10.1186/bcr3051

Ejemplares similares

Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: Prominent expression of P-cadherin
por: Ben Hamida, Azza, et al.
Publicado: (2008)

Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer
por: Jacquemier, Jocelyne, et al.
Publicado: (2009)

Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers
por: Letessier, Anne, et al.
Publicado: (2006)

High-Resolution Comparative Genomic Hybridization of Inflammatory Breast Cancer and Identification of Candidate Genes
por: Bekhouche, Ismahane, et al.
Publicado: (2011)

CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines
por: Zabouo, Gwladys, et al.
Publicado: (2009)

Molecular characterization of breast cell lines: a tool for breast cancer studies
por: Charafe-Jauffret, E, et al.
Publicado: (2005)

Genome profiling of ERBB2-amplified breast cancers
por: Sircoulomb, Fabrice, et al.
Publicado: (2010)

MARCKS protein overexpression in inflammatory breast cancer
por: Manai, Maroua, et al.
Publicado: (2016)

Kinome expression profiling and prognosis of basal breast cancers
por: Sabatier, Renaud, et al.
Publicado: (2011)

Candidate Luminal B Breast Cancer Genes Identified by Genome, Gene Expression and DNA Methylation Profiling
por: Cornen, Stéphanie, et al.
Publicado: (2014)

8q24 Cancer Risk Allele Associated with Major Metastatic Risk in Inflammatory Breast Cancer
por: Bertucci, François, et al.
Publicado: (2012)

Comparative genomic analysis of primary tumors and metastases in breast cancer
por: Bertucci, François, et al.
Publicado: (2016)

p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results.
por: Jacquemier, J., et al.
Publicado: (1994)

A seven-gene prognostic model for platinum-treated ovarian carcinomas
por: Sabatier, R, et al.
Publicado: (2011)

Nectin-4 is a new histological and serological tumor associated marker for breast cancer
por: Fabre-Lafay, Stéphanie, et al.
Publicado: (2007)

Similar response profile to neoadjuvant chemotherapy, but different survival, in inflammatory versus locally advanced breast cancers
por: Monneur, Audrey, et al.
Publicado: (2017)

The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial)
por: Penault-Llorca, Frédérique, et al.
Publicado: (2018)

Breast cancer stem cells: tools and models to rely on
por: Charafe-Jauffret, Emmanuelle, et al.
Publicado: (2009)

Targeting breast cancer stem cells: fishing season open!
por: Ginestier, Christophe, et al.
Publicado: (2010)

p53 and cancer stem cells: The mevalonate connexion
por: Ginestier, Christophe, et al.
Publicado: (2012)

Standards, Options and Recommendations: SOR organising committee: FNCLCC, Paris
Publicado: (2003)

Prediction of Early Breast Cancer Metastasis from DNA Microarray Data Using High-Dimensional Cox Regression Models
por: Zemmour, Christophe, et al.
Publicado: (2015)

ZNF703 gene amplification at 8p12 specifies luminal B breast cancer
por: Sircoulomb, Fabrice, et al.
Publicado: (2011)

ZNF703 gene amplification at 8p12 specifies luminal B breast cancer
por: Sircoulomb, Fabrice, et al.
Publicado: (2011)

Postoperative serum proteomic profiles and identification of biomarkers with prognosis value in high-risk early breast cancer patients
por: Gonçalves, A, et al.
Publicado: (2005)

Stromal Expression of MARCKS Protein in Ovarian Carcinomas Has Unfavorable Prognostic Value
por: Doghri, Raoudha, et al.
Publicado: (2017)

Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization
por: Sabatier, Renaud, et al.
Publicado: (2014)

Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study
por: Rahal, S., et al.
Publicado: (2015)

Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer
por: Guerin, Mathilde, et al.
Publicado: (2018)

The E2F4 prognostic signature is also predictive of the pathological response of breast cancer to chemotherapy
por: Bertucci, François, et al.
Publicado: (2015)

XPO1, therapeutic … and prognostic target in sarcomas
por: Bertucci, François, et al.
Publicado: (2016)

Poly(ADP-Ribose) Polymerase 1 (PARP1) Overexpression in Human Breast Cancer Stem Cells and Resistance to Olaparib
por: Gilabert, Marine, et al.
Publicado: (2014)

PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy
por: Bertucci, François, et al.
Publicado: (2015)

A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers
por: de Nonneville, Alexandre, et al.
Publicado: (2019)

Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival
por: Oberic, Lucie, et al.
Publicado: (2011)

Histopathological Spectrum of Soft-Tissue Tumors with Immunohistochemistry Correlation and FNCLCC grading: A North Indian Experience
por: Singh, Hena Paul, et al.
Publicado: (2017)

c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays
por: Garcia, S, et al.
Publicado: (2007)

Prognostic impact of hormone receptor- and HER2-defined subtypes in inflammatory breast cancer treated with high-dose chemotherapy: a retrospective study
por: Boudin, Laurys, et al.
Publicado: (2016)

Prognostic and predictive value of PDL1 expression in breast cancer
por: Sabatier, Renaud, et al.
Publicado: (2014)

The therapeutic response of ER+/HER2− breast cancers differs according to the molecular Basal or Luminal subtype
por: Bertucci, François, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_04b7ti0j98mqao00bgv9jno7m1